Loading...
•
Mar 31, 2021
Black Diamond Therapeutics Q1 2021 Earnings Report
Reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.
Key Takeaways
Black Diamond Therapeutics reported $290.1 million in cash, cash equivalents, and investments as of March 31, 2021. Patient enrollment and dosing in the Phase 1/2 clinical trial of BDTX-189 continue to track in line with projections. Initial Phase 1 clinical data for BDTX-189 will be presented at ASCO Annual Meeting.
Patient enrollment and dosing in the Phase 1/2 clinical trial of BDTX-189 continue to track in line with projections.
Pre-clinical data for BDTX-1535 presented at AACR Annual Meeting; program on track to enter the clinic in 2022.
Cash, cash equivalents, and investments of $290.1 million as of March 31, 2021, expected to be sufficient to fund operations into 2023.
Initial Phase 1 clinical PK, safety, and preliminary efficacy data for BDTX-189 to be presented at ASCO Annual Meeting
Black Diamond Therapeutics
Black Diamond Therapeutics
Forward Guidance
Black Diamond is focused on advancing its pipeline of MasterKey inhibitor therapies and expects to present initial clinical data for BDTX-189 at the ASCO Annual Meeting. The company anticipates IND filings for its BRAF and FGFR programs in 2022.
Positive Outlook
- Dose-escalation portion of the Phase 1 clinical trial of BDTX-189 is on track to complete in first half of 2021.
- Initial Phase 1 clinical PK, safety, and preliminary efficacy data for BDTX-189 to be presented at ASCO Annual Meeting.
- Phase 2 portion of the MasterKey-01 study is on track to begin in the second half of 2021.
- BDTX-1535 program on track to enter the clinic in 2022.
- Company anticipates IND filings for both BRAF and FGFR programs in 2022.
Challenges Ahead
- Success of product candidate development activities and planned IND-enabling and clinical trials is uncertain.
- Company's ability to execute on its strategy is subject to risks and uncertainties.
- Regulatory developments in the United States could impact forward-looking statements.
- Company's ability to fund operations is subject to risks.
- COVID-19 pandemic may impact clinical trials and pre-clinical studies, supply chain, and operations.